Products from TargetMol
TargetMol, based in Boston, Massachusetts, was founded in 2015 and is a drug screening expert in the life science community. The company offers diverse compound libraries, including FDA-approved libraries, and covers a broad spectrum of small molecule compounds such as inhibitors and agonists as well as recombinant proteins and natural products. TargetMol's products are used by researchers worldwide in areas such as cancer research, neurobiology, inflammation, immunology and metabolism.
More information at: www.targetmol.com
No results were found for the filter!
NEW
Axatilimab
Item number: TGM-T76915-10mg
Description: Axatilimab (SNDX-6352) is a human IgG4 antibody targeting the colony-stimulating factor 1 receptor (CSF-1R), which can be used for the study of immune system disorders and respiratory diseases. Target: CSF-1R, c-Fms. References: Arora M, et al. Phase 1 study of axatilimab (SNDX-6352), a CSF-1R...
| Keywords: | SNDX-6352 , UCB6352 , SNDX6352 , INCA034176 , UCB 6352 , INCA-034176 |
From 186.00€
*
NEW
Bafisontamab
Item number: TGM-T76916-1mg
Description: Bafisontamab (EMB-01) is a bispecific antibody targeting EGFR and cMET, exhibiting antitumor activity [1]. Target: c-Met/HGFR, EGFR
588.00€
*
NEW
Bepranemab
Item number: TGM-T76926-10mg
Description: Bepranemab (UCB 0107) is a humanized anti-tau monoclonal antibody of the IgG class for the study of Alzheimer's disease (AD) and tau protein disorders. Target: Microtubule Associated. References: Matthew E Barton, et al. Design of a patient- and investigator-blind, randomized, placebo-controlled study...
| Keywords: | RG-6416 , RG6416 , UCB0107 , UCB 0107 |
From 186.00€
*
NEW
Botensilimab
Item number: TGM-T76933-10mg
Description: Botensilimab (AGEN 1181), a humanized monoclonal antibody targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4), functions as an activator of both innate and adaptive immunity. It is currently being researched for its potential application in cancer treatment [1]. Target: Others
From 202.00€
*
NEW
Briakinumab
Item number: TGM-T76935-10mg
Description: Briakinumab (ABT-874) is a monoclonal antibody targeting IL-12, used in the study of psoriasis, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Target: Interleukin, IL Receptor. References: Kelly RL, et al. Target-independent variable region mediated effects on antibody...
| Keywords: | BSF415977 , ABT-874 , J 695 , A-796874.0 , ABT874 , BSF 415977 |
From 215.00€
*
NEW
Cendakimab
Item number: TGM-T76942-10mg
Description: Cendakimab (RPC4046) is a humanized monoclonal antibody targeting IL-13. It selectively targets the IL-13 receptor (IL13R-alpha1 and IL13R-alpha2), used in research on atopic dermatitis. Target: Interleukin. References: Tripp CS, et al. RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding...
| Keywords: | CC 93538 , ABT308 , CC93538 , ABT-308 , RPC4046 , RPC 4046 |
From 153.00€
*
NEW
Zenocutuzumab
Item number: TGM-T76948-10mg
Description: Zenocutuzumab (MCLA-128) is a humanized antibody targeting the extracellular domains of HER2 and HER3. It can be used for research on tumors driven by NRG1 gene rearrangement. Target: HER, EGFR. References: Schram AM, et al. Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for...
| Keywords: | R 040517 , MCLA128 , R040517 , PB 4188 , MCLA-128 , PB4188 |
From 374.00€
*
NEW
Zelminemab
Item number: TGM-T76949-10mg
Description: Zelminemab (AMG-301) is a humanized monoclonal antibody targeting the pituitary adenylate cyclase-activating polypeptide type I receptor (ADCYAP1R1) for use in neurological disorders. Target: AChR. References: Rubio-Beltrán E, et al. PACAP38 and PAC1 receptor blockade: a new target for headache? J...
| Keywords: | AMG301 , AMG-301 |
From 186.00€
*
NEW
Zansecimab
Item number: TGM-T76950-10mg
Description: Zansecimab (LY-3127804) is a monoclonal antibody targeting angiopoietin 2 (Ang 2) for the study of cardiovascular and immune diseases. Target: RAAS, Tie-2. References: Wang Y, et al. Angiogenesis as a potential treatment strategy for rheumatoid arthritis. Eur J Pharmacol. 2021 Nov 5,910:174500.
| Keywords: | LY3127804 , LY-3127804 |
From 159.00€
*
NEW
Certolizumab pegol
Item number: TGM-T76963-10mg
Description: Certolizumab pegol (Certolizumab) is a polyethylene glycolated and humanized anti-TNF-alpha monoclonal antibody for the study of autoimmune diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). Target: TNF. References: Deeks ED. Certolizumab pegol: a...
| Keywords: | CDP870 , CDP8 70 , PHA738144 , PHA-738144 , Certolizumab |
From 138.00€
*
NEW
Urabrelimab
Item number: TGM-T76965-10mg
Description: Urabrelimab (SRF-231) is a humanized antibody targeting CD47, with antitumor activity. It blocks the CD47-SIRPalpha interaction and is used in studies of advanced malignant solid tumors. Target: Interleukin, Others. References: Peluso MO, et al. The Fully human anti-CD47 antibody SRF231 exerts...
| Keywords: | SRF231 , SRF-231 |
From 187.00€
*
NEW
Tafolecimab
Item number: TGM-T76974-10mg
Description: Tafolecimab (IBI-306), a human IgG2 monoclonal antibody, specifically targets and binds to PCSK-9, thus inhibiting PCSK-9-mediated endocytosis of the LDL receptor. This action enhances the clearance of LDL-C, resulting in a decrease in LDL-C levels. Tafolecimab has potential applications in...
From 313.00€
*